Riferimento:
Ugeskr Laeger. 2010 Oct 25;172(43):2950-3.
Autori:
Mortensen J1, Oturai P, Højgaard L, Knigge U, Hansen CP, Martiný L, Rasmussen P, Kjaer A.
Fonte:
Ugeskr Laeger. 2010 Oct 25;172(43):2950-3.
Anno:
2010
Azione:
Analoghi della somatostatina marcati possono essere somministrati a pazienti con tumori neuroendocrini metastatici inoperabili.
Target:
Analoghi della somatostatina/tumori neuroendocrini metastatici.
ABSTRACT
Peptide receptor radionuclide therapy using somatostatin analogues labelled with beta-emitting isotopes can be given to patients with metastasized or inoperable neuroendocrine tumours provided these have increased uptake on octreotide scintigraphy. This is a brief review of the treatment principle, indications and contraindications and practices with (177)Lu-DOTATATE treatment used at Rigshospitalet. Side effects are generally mild and reversible. Severe long-term side effects are rare. The majority of patients will experience increased quality of life and partial tumour reduction or stabilization for a period of time. However, up to 20% will experience no treatment effect.
Sostanze: